Back to search results

Daily Amino Acid Supplementation for Parkinson's Disease

This study is looking at whether a special blend of amino acids, called Targeted Amino Acid Supplement (which includes Leucine, Tryptophan, Arginine, Taurine, Glutamate, and Tyrosine), can help people with Parkinson's disease. Researchers want to see if this supplement can improve your nutrition, how your body uses energy (metabolic function), your body's makeup (body composition), and your physical and mental abilities. You might be able to join if you are between 50 and 80 years old, have been diagnosed with Parkinson's disease, and have been taking dopamine replacement medication for at least two years. The study will compare the effects of the Targeted Amino Acid Supplement to a control (placebo) supplement. The study aims to enroll 30 participants, but its current status is unclear.

Study design
This is an interventional study that plans to enroll 30 participants. It will compare a Targeted Amino Acid Supplement to a placebo (an inactive substance).
What's involved
You will have measurements taken at the start of the study (Baseline), and again at 3 months and 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after starting the study, with measurements taken at 3 and 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07115563

Daily Amino Acid Supplementation for People With Parkinson's Disease

Recruiting
NAAges 50–90InterventionalPrevention
Cristina Colon-Semenza
~30 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:Targeted Amino Acid SupplementControl (placebo)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Amino Acid bioavailability (Lysine, Tryptophan, Arginine, Glutamate, Leucine, Taurine, Glutathione)
Measured over Baseline, 3 months, and 6 months
+2 more outcomes measured

Conditions

Parkinson Disease (PD)

Explore related trials

Parkinson Disease

NCT07115563

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UConn Health

    Farmington, Connecticutstudy coordinator listed

    Recruiting

  • University of Connecticut

    Storrs, Connecticutstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Carlos Rehbein, MS
[email protected]
860-634-8203
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male and Females.
50-80 Years.
Previous diagnosis of idiopathic Parkinson's Disease by patient report.
Use of dopamine replacement medication (e.g. levodopa) for at least 2 years.
On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.

Exclusion

Apparent cognitive impairment as determined by phone screening (Telephone Interview for Cognitive Status \<29).
Diagnosis of Parkinsonism or atypical Parkinson's Disease.
Prescription of Dopamine antagonist.
Any unstable medical condition.
Use of Deep Brain Stimulation.
Gastric or Bowel resection surgery.
Contraindications to blood draw.

What this trial measures

  • Amino Acid bioavailability (Lysine, Tryptophan, Arginine, Glutamate, Leucine, Taurine, Glutathione)Baseline, 3 months, and 6 months

    Circulating amino acid concentrations will be measured from blood samples using high performance liquid chromatography using a solid phase column specifically designed to test amino acids (e.g. 00F-4435-E0, Phenomenex, USA) along with appropriate column guards (e.g. AJ0-7597 \& KJ0-4282, Phenomenex, USA) and liquid phases. This analysis will be performed at the Laboratory of Mass Spectroscopy and Omics Analysis.

  • Oxidative stressBaseline, 3 months, 6 months

    Oxidative stress will be measured using a total antioxidant power test (e.g. ab65329, ABCAM, USA). It is a quantitative bioassay and will be performed using the laboratory facilities.

  • Oxidative stressBaseline, 3 months, and 6 months

    Oxidative stress will be assessed with reduced/oxidized glutathione assays (e.g. ab138881, ABCAM, USA). It is a quantitative bioassay and will be assessed using laboratory facilities.